Molecular targeted therapy in colorectal cancer;Molekylært rettet behandling av kolorektal cancer

Tidsskrift for den Norske Laegeforening

Volumn 128, Issue 2, 2008, Pages 190-193

  Ree, Anne Hansen ^a,b   Bratland, Åse ^b   Dueland, Svein ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR;

COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METASTASIS; MORTALITY; REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; CYTOSTATIC AGENTS; HUMANS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 38749086877     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Chambers AF, Groom AV, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-72.
2. Gasparini G, Longo R, Toi M et al. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2005; 2: 562-77.
3. Macarulla T, Ramos FJ, Capdevila J et al. Novel targets for anticancer treatment development in colorectal cancer. Clin Colorectal Cancer 2006; 6: 265-72.
4. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
5. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-5.
6. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). 2007 Gastrointestinal Cancers Symposium; abstract 238. www.asco.org/portal/site/ ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID= 45&abstractID=10580 (16.11.2007).
7. Sugrue MM, Kozloff M, Hainsworth J et al. Safety and effectiveness of bevacizumab plus chemotherapy in elderly patients with mCRC: results from the BRiTE registry. 2007 Gastrointestinal Cancers Symposium; abstract 345. www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/? vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=45&abstractID=10653 (16.11.2007).
8. Giantonio BJ, Levy DE, O'dwyer PJ et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 2006; 17: 1399-403.
9. de Gramont A, Tournigand C, André T et al. Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol 2007; 34: S37-40.
10. Czito BG, Bendell JC, Willett CG et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys 2007; 68: 472-8.
11. Nygren P, Sørbye H, Österlund P et al. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report. Acta Oncol 2005; 44: 203-17.
12. Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 2005; 5: 171-93.
13. Tabernero J, Salazar R, Casado E et al. Targeted therapy in advanced colon cancer: the role of new therapies. Ann Oncol 2004; 15 (suppl 4): iv55-62.
14. Van Cutsem E, Nowacki M, Lang I et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. 2007 Annual Meeting of the American Society of Clinical Oncology; abstract 4000. Philadelphia, PA: American Society of Clinical Oncology, 2007.
15. Sobrero AF, Fehrenbacher L, Rivera F et al. Randomized phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin-based therapy: the EPIC trial. 2007 Annual Meeting of the American Association for Cancer Research; abstract 3536. Philadelphia, PA: American Society of Clinical Oncology, 2007.
16. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med 2004; 351: 337-45.
17. Souglakos J, Kalykaki A, Vamvakas L et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 2007; 18: 305-10.
18. Saltz LB, Meropol NJ, Loehrer PJ sr. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
19. Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-21.
20. Hofheinz RD, Horisberger K, Woernle C et al. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66: 1384-90.
21. Machiels JP, Sempoux C, Scalliet P et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 2007; 18: 738-44.
22. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6: 29-31.
23. Saltz LB, Lenz HJ, Kindler H et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. 2005 Gastrointestinal Cancers Symposium; abstract 169b. www.asco.org/portal/site/ASCO/menuitem. 34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID= 36&index=y&abstractID=10273 (16.11.2007).
24. Amgen discontinues Vectibix™ treatment in PACCE trial evaluating Vectibix™ as part of triple combination regimen. Pressemelding (Amgen) 22.3.2007. www.reuters.com/article/inPlayBriefing/ idUSIN20070322173707AMGN20070322 (16.11.2007).
25. Drosten M, Putzer BM. Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat Clin Pract Oncol 2006; 3: 564-74.
26. Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer - more than skin deep. J Clin Oncol 2005; 23, 5374-85.
27. Rao S, Cunningham D, de Gramont A et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 2004; 22: 3950-7.
28. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. Oncogenic activation of the RAS/RAF-signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-8.
29. Sträter J, Hinz U, Walczak H et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 2002; 8: 3734-40.